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The quantitative viral outgrowth assay (QVOA) provides a precise minimal estimate of the reservoir of resting
CD4+ T-cell infection (resting cell infection [RCI]). However, the variability of RCI over time during antiretro-
viral therapy (ART), relevant to assess potential effects of latency-reversing agents or other interventions, has
not been fully described. We performed QVOA on resting CD4+ T cells obtained via leukapheresis from 37
human immunodeficiency virus (HIV)–infected patients receiving stable suppressive ART for a period of 6
years. Patients who started ART during acute (n = 17) or chronic (n = 20) HIV infection were studied once
HIV RNA levels were <50 copies/mL for ≥6 months. Using random effects analysis of 160 RCI measurements,
we found that RCI declined significantly over time (P < .001), with an estimated mean half-life of 3.6 years (95%
confidence interval, 2.3–8.1 years), remarkably consistent with findings of prior studies. There was no evidence
of more rapid decay in acute versus chronic HIV infection (P = .99) for patients suppressed≥6 months. RCI was
reliably estimated with longitudinal measurements generally showing <2-fold variation from the previous mea-
sure. When QVOA is performed in this format, RCI decreases of >6-fold were rare. We suggest that a 6-fold
decline is a relevant threshold to reliably identify effects of antilatency interventions on RCI.
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Latent, persistent infection of resting memory CD4+
T cells by human immunodeficiency virus (HIV) type 1
is established early after initial viremia [1–3]. This rare
but extremely stable pool of cells contains replication-
competent, integrated provirus that may produce infec-
tious virus on activation of the host cell. Resting cell
infection (RCI) is the major obstacle to a cure, allowing
the virus to persist even in patients receiving long-term
antiretroviral therapy (ART) and in the presence of im-
mune surveillance [4–6].
Initial estimates of the half-life of RCI, as low as
6 months, led to hopes that eradication could be achi-
eved simply with prolonged ART [7–9]. Estimates for
eradication with continuous therapy in patients who
started ART early in infection were as low as 7.7 years
[7]. However, after the initial rapid phase of RCI decay
after ART initiation, a much slower phase of decay is esti-
mated to have a half-life of approximately 44 months
[6, 10]. Thus, eradication based on ART and natural decay
alone would take up to 73.4 years in a patient with a res-
ervoir size of just 106 cells [10].
Modeling studies have suggested that activation of
latently infected cells can maintain persistent low-level
viremia (LLV) and produce intermittent viral blips
while replenishing the latent reservoir through homeo-
static proliferation and/or de novo infection events [5].
This persistent LLV, detectable with an ultrasensitive
single-copy assay (SCA) [11], has been observed more
frequently in patients with a higher frequency of RCI
in a small cohort of patients starting ART during either
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acute HIV infection (AHI) or chronic HIV infection (CHI) [3].
ART during the acute phase of infection restricts but does not
accelerate decay of RCI [3]. Given the many factors at play in
maintaining RCI and the absence of any accelerated decay
rate in patients with AHI, it has become apparent that disrup-
tion of latency will be necessary in therapeutic approaches to
clear latent HIV infection.
Current eradication strategies, such as treatment with laten-
cy-reversing agents, aim to eliminate RCI. Their effectiveness
can be evaluated by measuring RCI over time in the presence
of ART, after a therapeutic intervention. Although the quantita-
tive viral outgrowth assay (QVOA) is currently the reference
standard for measuring RCI, it has also been described as widely
variable and inaccurate [12, 13]. QVOA provides an estimate of
the frequency of resting CD4+ T cells carrying inducible, repli-
cation-competent viral genomes. Intact, noninduced proviruses
have been characterized that are capable of replication but not
detectable with QVOA, suggesting that QVOA may underesti-
mate the true size of the latent reservoir [13]. In this work, Ho
et al [13] suggested that serial induction of pools of infected cells
may allow the quantitation of formerly noninduced viruses. To
date, however, no polymerase chain reaction (PCR)–based
assay provides a precise and internally consistent indication of
the amount of replication-competent HIV in resting cells; such as-
says often detect defective proviruses that cannot produce infec-
tious virus [12, 14, 15]. Therefore, measurements of any change
in RCI using a PCR-based method of detection may fail to detect
a depletion of latently infected cells capable of producing
infectious virus, because this will be masked by a large pool of
cells containing defective proviruses insensitive to any intervention
[12, 13].
Reliable measurement of RCI is necessary to assess potential
effects of antilatency interventions. To our knowledge QVOA
is the only reliable method by which replication-competent latent
virus has been quantitated longitudinally. However, the variabil-
ity of RCI measurements over time in patients receiving ART has
not been fully described. Understanding RCI variability can help
in determining a threshold to identify the effects of antilatency




We studied a cohort of 37 subjects, of whom 17 were identified
during AHI (plasma HIV RNA detected and HIV Western blot
negative). All patients with AHI started ARTwithin 45 days of the
estimated date of infection, except 1 who started ART 6 months
after infection (early infection). All patients had been aviremic
(<50 copies/mL plasma RNA) for≥6months. All patients provid-
ed written informed consent, and studies were approved by the
University of North Carolina Institutional Review Board.
QVOA and SCA
Patients underwent continuous-flow leukapheresis. Resting
CD4+ T cells were isolated via negative selection, and RCI was
determined with the QVOA, as described elsewhere [16]. Briefly,
30–65 million highly purified CD4+ resting cells were maximally
stimulated in limiting dilutions with phytohemagglutinin (PHA)
(Remel-PHA; Thermo Scientific), interleukin 2, and irradiated
peripheral blood mononuclear cells (PBMCs) from a seronega-
tive donor. Cultures were targeted twice with CCR5-high,
CD8-depleted, PHA-stimulated PBMCs from an uninfected
donor. To minimize introducing variation to the QVOA caused
by using PBMCs from different donors, assays were performed
with matched patient-donor pairs. Culture supernatants were
tested for P24 expression by enzyme-linked immunosorbent
assay on day 15, with confirmation on day 19. A maximum like-
lihood probability method was used to estimate the frequency of
RCI for each patient, with results reported as infectious units per
million resting CD4+ T cells (IUPM) [17, 18]. In a selected group
of patients, LLV was measured using an ultrasensitive, quantita-
tive real-time, reverse-transcriptase-PCR SCA that could quantify
plasma HIV-1 RNA to a limit of detection of 1 copy/mL [11].
Statistical Analysis
Random effects regression on log10-transformed RCI measure-
ments was used to evaluate RCI decay [10], compare initial lev-
els and decay between AHI and CHI groups, and estimate
sources of variability, analyzing RCI measurements obtained
≥12 months after ART initiation. For 4 time points (involving
3 subjects) with all negative cultures, RCI was estimated assum-
ing that 1 culture at the highest input cells was positive, and
one-half of this RCI was used for the statistical analyses; for 1
time point with all positive cultures, RCI was estimated assum-
ing that 1 culture at the lowest input of cells was negative and
analyzed at 2 times this estimated RCI. In patients for whom
SCA was available, Pearson correlation was used in a univariate
analysis to examine the relationship between mean SCA and
IUPM values; SCA measurements below the assay limit were
imputed as half of the reported detectable SCA value before cal-
culation of the subject-specific mean SCA value.
RESULTS
RCI Decay in Virally Suppressed Patients
Overall, 37 participants (17 treated during AHI and 20 during
CHI; aged 19–66 years) were studied, and provided a total of
160 individual QVOA measurements (median number, 4 per
patient; median interval, 3 months; median RCI follow-up per
patient, 1.2 years). The median ART duration at first RCI mea-
surement was 21 months in the AHI and 78 months in the CHI
cohort. The CD4+ T-cell count at first RCI was 744 cells for AHI
and 584 cells for CHI. The mean RCI level at first measurement
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was 0.42 IUPM, well within the range of previously reported
values [10].
RCI declined significantly over time (P < .001), with an esti-
mated mean half-life of 3.6 years (95% confidence interval, 2.3–
8.1 years). There was no evidence of more rapid decay for AHI
compared with CHI (P = .99) (Figure 1).
In a sensitivity analysis restricted to 21 subjects with sus-
tained viral suppression and no interruptions in ART (9 with
AHI and 12 with CHI, contributing a total of 91 RCI measure-
ments), the estimated mean RCI half-life was 3.3 years (95%
confidence interval, 2.0–8.0 years). There was no evidence
(P = .68) that the half-life differed between this group and sub-
jects with viral blips or LLV during the time period of RCI mea-
surement (all <400 copies/mL; n = 13) or ART interruptions
within 1 year of RCI measurement (n = 3).
Reproducibility of the QVOA
The ability to reliably measure RCI is critical for assessing poten-
tial effects of antilatency interventions, specifically the effects on
the replication-competent reservoir. The variability betweenmul-
tiple measurements could provide important information to help
determine a threshold for identifying these effects and conduct
power analyses to design future studies. To that end, we assessed
the variability over time in 160 individual RCI measurements.
Considering only within-subject variability, the estimated
standard deviation for the change in log10 RCI was 0.38. Under
assumed normality of RCI variability, this implies that a >2.5-fold
RCI decrease within 3 months has a likelihood of 0.16 (16%) dur-
ing stable ART with a RCI half-life of 3.6 years. A >6-fold RCI
decrease has a likelihood of 0.023 (2.3%). Empirically evaluating
the 123 pairs of consecutive RCI measurements, 81 (66%) had
Figure 1. Decay of resting CD4+ T-cell infection in virally suppressed patients. Each data point represents an independent measurement. Each symbol/
shape represents one patient. Blue symbols represent patients treated during acute human immunodeficiency virus (HIV) infection and red symbols those
treated during chronic infection. Zidovudine (AZT) and didanosine (DDI) were the first line of therapy for 3 patients treated during chronic HIV infection.
Abbreviation: IUPM, infectious units per million resting CD4+ T cells.
Figure 2. Reproducibility of the quantitative viral outgrowth assay. Multiple independent measurements of resting cell infection (RCI) in 37 suppressed
patients over time show the limited variability of the assay. RCI was reliably estimated with longitudinal measurements generally showing <2-fold variation
from the previous measurement. Abbreviation: IUPM, infectious units per million resting CD4+ T cells.
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<2-fold increases or decreases, 21 (17%) had >2.5-fold decreases,
and 3 (2.4%) had >6-fold decreases (Figure 2).
Correlation Between Low-Level Viremia and Reservoir Size
The initiation of ART leads to the rapid decline of viremia to
below the limit of detection for conventional PCR assays. How-
ever, in approximately 80% of patients receiving ART, LLV detect-
able only with sensitive PCR assays is stable and unresponsive to
intensification of therapy [19,20].The source of this viremia is cur-
rently not well characterized, but it has been postulated to be the
release of virions from cells infected before ART administration.
We examined the relationship between RCI and LLV, subjecting
IUPM and SCA values from 26 patients with available LLV mea-
surements to a univariate analysis using Pearson correlation. We
observed a positive correlation (Figure 3; Pearson’s r = 0.531)
between the size of the resting CD4+ T-cell reservoir and LLV,
consistent with previous reports [3].
DISCUSSION
Memory resting CD4+ T cells remain the most well-defined res-
ervoir of quiescent, archival, replication-competent HIV. Al-
though not completely understood, infection of activated CD4+
T cells as they are transitioning to a resting memory state may
be the primary mechanism by which latency is established; direct
infection of resting cells has also been demonstrated [10, 21]. Sev-
eral studies have suggested that HIV latency is regulated by the
samemechanisms that govern host cell gene expression, including
epigenetic transcriptional silencing, availability, and recruitment
of host transcription factors and transcriptional interference (re-
viewed in [22]).There is clear evidence that cells that contain HIV
DNA integrants can undergo homeostatic proliferation [23–25],
and if these genomes are replication competent they will contrib-
ute to persistent infection. The use of the QVOA therefore re-
mains the reference standard for quantifying quiescent HIV in
memory resting CD4+ T cells, providing a true measure of repli-
cation-competent inducible provirus.
Analysis presented here shows that RCI decays with a half-life
of 3.6 years or 43 months, a finding consistent with the 44-
month half-life seen in studies by Siliciano et al [10]. From
these measurements, it has been estimated that eradication
based on ART and natural decay alone could take up to 73
years [6, 10]. Furthermore, we observed a correlation between
RCI and LLV suggesting that, in at least a subset of patients,
resting CD4+ T cells may be a source of this residual viremia.
This is puzzling, given the stability of RCI over years, because
it might be expected that the expression of virions from former-
ly latently infected resting T cells should lead to significant
decay of this reservoir. Evidence has suggested that proviral ge-
nomes may undergo either homeostatic or dysfunctional prolif-
eration [23–25], although the proportion of these genomes that
are actually replication competent is unclear. Most of the ge-
nomes in transitional or effector memory subsets may in fact
be defective [26]. A model that could link these disparate obser-
vations would hold that the rate of homeostatic proliferation in
central memory cells that were latently infected with replica-
tion-competent genomes was perfectly matched by the rate at
which this same cell population was stochastically activated to
release virions. Therefore, clearance of residual infection will re-
quire targeting and disruption of the latent reservoir with an ef-
ficiency that significantly exceeds this proliferation rate of the
replication-competent reservoir.
The ability of latency-reversing agents to induce expression of
latent provirus is under intensive study (reviewed in [27]), and
studies of the HDAC inhibitors vorinostat, panobinostat, and
romidepsin have advanced into clinical trials [27]. Inducing ex-
pression of previously silenced promoters could provide an op-
portunity for immune recognition and clearance of infected
cells, and therefore complimentary interventions, such as im-
mune-augmentation therapies, are being studied for their ability
to clear latent HIV infection.
However, to assess the effectiveness of such eradication strat-
egies, the ability to reliably measure the frequency of RCI is es-
sential. QVOA is the only method by which IUPM values have
been longitudinally quantitated, and in the current study we as-
sessed the variability of the assay, finding <2-fold variation in
most cases. This is consistent with a model estimate of the like-
lihood of change based on within-subject variability. Change in
IUPM values can be used to assess the effectiveness of antila-
tency interventions. Our results suggest that a >6-fold change
would be rare during stable, suppressive ART and so should
serve as a potential threshold for reduction in IUPM values
that is not likely to represent natural variation. This finding is
based on QVOA using large number of cells obtained from
Figure 3. Correlation between low-level viremia (LLV) and the size of the
resting CD4+ T-cell reservoir. In 26 patients for whom LLV measurements
were available, Pearson’s correlation was used in a univariate analysis to
examine the relationship between mean single-copy assay (SCA) and infec-
tious units per million resting CD4+ T cell (IUPM) values.
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leukapheresis; with fewer cells examined, variability in RCI is
expected to be larger. The magnitude of this threshold is both
appropriate and significant because only large reductions in the
frequency of RCI are expected to be clinical relevant. Results of
a 2014 modeling study [28] suggest that reductions in the fre-
quency of RCI on the order of several logs will be necessary to
significantly delay time to viral rebound after ART interruption.
In this regard, it has also been demonstrated that QVOA un-
derestimates the frequency of RCI [13], because in a coculture
assay a single exposure to even maximal mitogen stimulation
will not result in the recovery of every replication-competent
virus [13]. In this study of 8 patients, the frequency of CD4+
T cells encoding proviruses expressing apparently full-length
HIV RNA was 4–50-fold greater than that of cells from which
replication-competent HIV could be recovered, after a single
stimulation, although recovery could be increased by serial
stimulations. Therefore, the RCI as quantified by QVOA reflects
a minimal measurement of the true latent reservoir, and the
number of noninduced proviruses represents a maximal mea-
surement of this reservoir. However, given current knowledge,
a significant depletion of latent infection shown by QVOA
would be expected to correlate with a depletion of the total rep-
lication-competent latent reservoir. Until improved assays are
available, the documentation of a depletion of RCI by a >6-
fold decline in QVOA measurements would represent a mean-
ingful step toward the goal of HIV eradication.
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